Formulary Group work programme


The Group meets monthly on the third Tuesday of each month. The following list notes medicines that will be scheduled for review in the next three to four months. This list is indicative and may be subject to change.

Adalimumab (Humira®) - SMC 1143/16 - Formulary Group decision will be published by 1st June 2016. (Indication: for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy).

Bevacizumab (Avastin®) - SMC 1135/16 - Formulary Group decision will be published by 1st June 2016. (Indication: for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix, in combination with paclitaxel and cisplatin in patients who cannot receive platinum therapy).

Camellia sinensis (green tea) leaf extract (Catephen®) - SMC 1133/16 - Formulary Group decision will be published by 1st June 2016. (Indication: for the cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years).

Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide film-coated tablet (Genvoya®) - SMC 1142/16 - Formulary Group decision will be published by 1st June 2016. (Indication: for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus-1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir).

Eribulin (Halaven®) - SMC 1065/15 Formulary Group decision will be published by 1st June 2016. (Indication: for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressive disease after at least two prior chemotherapeutic regimens for advanced disease. Prior therapy should have included capecitabine if indicated, an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments).

Fulvestrant (Faslodex®) - SMC 114/04 - Formulary Group decision will be published by 1st June 2016. (Indication: for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on therapy with an anti-oestrogen).

Horse Antigen - FG1 390/15 - In progress. (Indication: for the treatment of aplastic anaemia). 

Isavuconazole (Cresemba®) - SMC 1129/16 - Formulary Group decision will be published by 1st June 2016.
(Indication : for the treatment of adults with: 
- invasive aspergillosis 
- mucormycosis in patients for whom amphotericin B is inappropriate).

Ivermectin (Soolantra®) - SMC 1104/15 - Formulary Group decision will be published by 1st June 2016. (Indication: for the topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients).

Lenalidomide (Revlimid®) - SMC 1096/15 - Formulary Group decision will be published by 1st June 2016. (Indication: for the treatment of adult patients, who are unsuitable for thalidomide-containing regimens, with previously untreated multiple myeloma who are not eligible for transplant).

Pembrolizumab (Keytruda®) - SMC 1086/15 - In progress (Indication: as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously untreated with ipilimumab).

Sacubitril/valsartan (Entresto®) - SMC 1132/16 - Formulary Group decision will be published by 1st June 2016. (Indication:  for treatment of symptomatic chronic heart failure with reduced ejection fraction in adult patients).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END